Tabuk

All products

1. what is ethics? what is business ethics?

1. what is pharmacovigilance (pv)?

1.1 introduction

1.1 introduction

1.1 module content

1.2 classification

1.2 epidemiology

1.3 epidemiology

1.3 normal physiology

1.4 pathophysiology

1.4 physiology & pathophysiology

1.5 etiologies & risk factors

1.5 etiology & risk factors

1.6 diagnosis & clinical presentation

10. to whom do we report?

11. step by step to report the adr?

12. lack of efficacy & quality complaints

13. step by step to report the quality complaint

14. pharmacovigilance tabuk contact information

15. summary video

2. aims of pharmacovigilance

2. what is compliance?

2.1 clinical presentation

2.1 important definitions

2.1 prevalence and incidence

2.1 the circulatory system

2.2 cardiovascular system components and functions

2.2 causes of dementia

2.2 glycemic goals & hypoglycemia

2.3 other diagnostic procedures

2.3 pharmacological approach to glycemic treatment; choice of glucose-lowering therapy

2.4 diagnosis of familial hypercholesterolemia

2.4 the blood vessels

2.5 arterial blood pressure

2.6 factors affecting blood pressure

2.7 pathophysiology of hypertension

3. benefits versus risks

3. why should we comply?

3.1 guidelines definitions of blood pressure

3.1 pathogenesis

3.1 pathophysiology and introduction

3.1 treatment goals

3.1 type 1 diabetes mellitus

3.10 complications

3.11 evidence-based medicine

3.12 the future of alzheimer’s disease

3.2 definition and pathology

3.2 dopamine movement

3.2 epidemiology of hypertension

3.2 pharmacological treatment

3.2 type 2 diabetes mellitus

3.3 epidemiology

3.3 non-pharmacological approaches

3.3 non-pharmacological treatment

3.3 types of hypertension

3.4 management of older adults

3.4 risk factors

3.4 risk factors of hypertension

3.5 forms and stages

3.5 management of patients with chronic kidney disease (ckd)

3.6 diagnosis and assessment tools

3.6 management of diabetes in pregnancy

3.7 clinical presentation and classification

3.9 medications

4. how to ensure compliance

4. understanding pharmacovigilance

4.1 clinical presentation

4.1 demographics

4.1 familial hypercholesterolemia

4.1 regular monitoring parameters

4.2 diabetes mellitus

4.2 environmental risk factors

4.2 factors influencing prognosis

4.2 short-term complications of poorly managed diabetes

4.3 assessment of cv risk

4.3 genetic risk factors

4.3 long-term complications of poorly managed diabetes

4.4 2019 acc/aha treatment goals

4.4 take home messages

5. important concepts & definitions

5. what is code of conduct? why is it important?

5.1 2017 acc/aha treatment goals and recommendations

5.1 motor symptoms

5.2 non-motor symptoms

5.3 sympatholytics

5.4 adrenoreceptor blockers

5.5 vasodilators

5.6 calcium channel blockers

5.7 renin angiotensin inhibitors

5.8 clinicians perspectives and special people groups

6. why we must report adr?

6.1 bp thresholds and recommendations for treatment and follow up

6.1 complications

6.1 disease stages

6.2 advancement of disease stages in correlation with disability

6.2 take-home messages

7. interactions with hcps

7. what do we report?

7.1 goal of treatment

7.1 high blood pressure complications

7.2 therapy options

7.3 general treatment principles

7.4 medications

8. interactions with the public

8. what information should be reported?

8.1 special situations

9. disclosure & transparency

9. when and where to report?

test your knowledge

test your knowledge

test your knowledge

test your knowledge

test your knowledge

test your knowledge

test your knowledge

test your knowledge

test your knowledge

test your knowledge

test your knowledge

test your knowledge